{
    "type": "VariantTherapeuticResponseProposition",
    "predicate": "sensitivity",
    "description": "Treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)",
    "geneContextQualifier": "RET",
    "objectTherapeutic": "Selpercatinib [Retevmo]"
}